Skip to main content
SpringerLink
Log in

Docetaxel–Anthracycline Combinations in Metastatic Breast Cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The taxanes and anthracyclines have emerged as the most active agents for treating women with advanced breast cancer. As such, investigation of the two drug classes in combination regimens has been eagerly pursued. The rationale for combining docetaxel with an anthracycline includes high clinical activity of each individual agent, lack of complete clinical cross resistance, and non-overlapping toxicity profiles. Phase II trials of the docetaxel combinations with either doxorubicin or epirubicin showed high activity, with acceptable tolerability in patients with metastatic breast cancer. Consequently, three randomized trials have compared docetaxel–anthracycline-based regimens with standard anthracycline-based polychemotherapies as first-line therapy for women with advanced breast cancer. Improved outcome was reported in favor of the docetaxel–anthracycline combinations, with manageable hematologic toxicity and favorable non-hematologic safety profiles. Therefore, docetaxel–anthracycline combinations represent a validated option in first-line treatment for women with advanced breast cancer, and are further evaluated as adjuvant treatment for early stage breast cancer, with already promising prospects and the potential to change the natural history of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M et al.: Prospective randomized trial of docetaxel versus mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17: 1413-1424, 1999

    Google Scholar 

  2. Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H, Bergh J: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomized phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194-1201, 1999

    Google Scholar 

  3. Bonneterre J, Monnier A, Roche H et al.: Taxotere versus 5-fluorouracil + Navelbine in patients with metastatic breast cancer as 2nd line chemotherapy. Breast Cancer Res Treat 50: 261, 1997 (abstract 564)

    Google Scholar 

  4. Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15: 1906-1915, 1997

    Google Scholar 

  5. Schüller J, Czejka M, Kletzl H, Wirth M, Springer B, Kriwanek S, Terkola R, Schernthaner G: Doxorubicin (DOX) and Taxotere® (TXT): a pharmacokinetic (PK) study of the combination in advanced breast cancer. Proc Am Soc Clin Oncol 17: 205a, 1998 (abstract 790)

    Google Scholar 

  6. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C et al.: Paclitaxel by 3-hour infusion in combination with bolus doxurubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688-2699, 1995

    Google Scholar 

  7. Gehl J, Boesgaard M, Paaske T, Vittrup Jensen B, Dombernowsky P: Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 7: 687-693, 1996

    Google Scholar 

  8. Misset JL, Diéras V, Gruia G, Bourgeois H, Cvitkovic E, Kalla S, Bozec L, Beuzeboc P, Jasmin C, Aussel JP, Riva A, Azli N, Pouillart P: Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 10: 553-560, 1999

    Google Scholar 

  9. Sparano JA, O'Neill A, Schaefer PL, Falkson CI, Wood WC: Phase II trial of doxorubicin and docetaxel plus granulocytecolony stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group study E1196. J Clin Oncol 18: 2369-2377, 2000

    Google Scholar 

  10. Diéras V, Barthier S, Beuzeboc P et al.: Phase II study of docetaxel in combination with doxorubicin as 1st line chemotherapy of metastatic breast cancer. Breast Cancer Res Treat 50: 262, 1998 (abstract 266)

    Google Scholar 

  11. Baltali E, Ozisik Y, Guler N, Firat D, Altundag K: Combination of docetaxel and doxorubicin as first-line chemotherapy in metastatic breast cancer. Tumori 87: 18-19, 2001

    Google Scholar 

  12. Nabholtz J-M, Mackey JR, Smylie M, Paterson A, Noel DR, Al-Tweigeri T, Tonkin K, North S, Azli N, Riva A: Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 19: 314-321, 2001

    Google Scholar 

  13. Pagani O, Sessa C, Nole F, Crivellari D, Lombardi D, Thurlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Zucchetti M, D'Incalci M, Goldhirsch A: Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Ann Oncol 11: 985-991, 2000

    Google Scholar 

  14. Mavroudis D, Alexopoulos A, Ziras N, Malamos N, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Tsavaris N, Potamianou A, Rigatos G, Georgoulias V: Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study. Ann Oncol 11: 1249-1254, 2000

    Google Scholar 

  15. Viens P, Roche H, Kerbrat P, Fumoleau P, Guastalla JP, Delozier T: Epirubicin-docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study. Am J Clin Oncol 24: 328-335, 2001

    Google Scholar 

  16. Milla-Santos A, Milla L, Rallo L, Solano V: High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer. Am J Clin Oncol 24: 138-142, 2001

    Google Scholar 

  17. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized multicenter, phase III trial. J Clin Oncol 21: 968-975, 2003

    Google Scholar 

  18. Nabholtz J, Paterson A, Dirix L, Dewar J, Chap L, Martin M, Chan S, Tang S, Dugan W, Gil M, Zaluski C, Russel C, Vogel C, Borg-Olivier O, Riva A, Murawsky M, Azli N, Efremidis A: A phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 20: 22a, 2001 (abstract 83)

    Google Scholar 

  19. Mackey JR, Paterson A, Dirix LY, Dewar J, Chap L, Martin M, Chan S, Tang SC, Dugan W, Gil M, Zaluski J, Russel C, Vogel C, Efremedis A, Appia F, Brunel E, Hatteville L, Azli N, Nabholtz JM: Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 21: 25a, 2002 (abstract 137)

    Google Scholar 

  20. Bonneterre JM, Dieras V, Tubiana-Hulin M, Bougnoux P, Bonneterre M-EA, Bendahmane B: Epirubicin/docetaxel (ET) versus 5FU/epirubicin/cyclophosphamide (FEC) combinations as first line chemotherapy in patients with metastatic breast cancer [MBC]. Breast Cancer Res Treat 69: 215, 2001 (abstract 27)

    Google Scholar 

  21. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21: 588-592, 2003

    Google Scholar 

  22. Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 20: 3114-3121, 2002

    Google Scholar 

  23. Luck HJ, Thomssen C, Untch M, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Moebus V, Steinfeld D, Bauknecht T, Schroeder W, Jackisch C: Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC): epirubicin/paclitaxel (ET) epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group. Proc Am Soc Clin Oncol 19: 73a, 2000 (abstract 280)

    Google Scholar 

  24. Carmichael J: UKCCR trial of epirubicin and cyclophosphamide (EC) vs. epirubicin and Taxol (ET) in the first line treatment of women with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 20: 22a, 2001 (abstract 84)

    Google Scholar 

  25. Jassem J, Pienowski T, Pluzanka A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S, Weil C: Central &; Eastern Europe and Israel Pacitaxel Breast Cancer Study Group: doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 9: 1707-1715, 2001

    Google Scholar 

  26. Nabholtz JM, Cantin J, Chang, Guevin R, Patel R, Tkaczuk K, Vodvarka P, Lindsay MA, Reese D, Riva A, Mackey J: Randomized double-blind phase III trial comparing granulocyte colony-stimulating factor (G-CSF) to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide (TAC): results of the BCIRG 004 trial. Clin Breast Cancer 3(4): 268-275, 2002

    Google Scholar 

  27. Nabholtz J-M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Vogel C, Weaver C, Walley B, Martin M, Chap L, Tomiak E, Juhos E, Guevin R, Howell A, Hainsworth J, Fornander T, Blitz S, Gazel S, Loret C, Riva A: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: interim analysis of BCIRG 001 Study. Proc Am Soc Clin Oncol 21: 36a, 2002 (abstract 141)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Therapy Development Program and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA

    Jean-Marc A. Nabholtz

Authors
  1. Jean-Marc A. Nabholtz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nabholtz, JM.A. Docetaxel–Anthracycline Combinations in Metastatic Breast Cancer. Breast Cancer Res Treat 79 (Suppl 1), 3–9 (2003). https://doi.org/10.1023/A:1024369220605

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1024369220605

Search

Navigation